Grenoble, France-based UroMems — which has its U.S. headquarter in Minneapolis — developed the AUS to treat stress urinary incontinence (SUI). It expects the funds to support large-scale U.S. and European pivotal clinical trials for the implant, called UroActive. This could pave the way for future regulatory submissions.
Powered by a MyoElectroMechanical system (MEMS), UroActive goes into the urethral duct in men and bladder neck in women. It’s controlled by a patient’s activity without the need for manual adjustments. This provides patients ease of use and better quality of life compared to other options. The company previously had positive early feasibility data in a study of six men, then reported the first-ever female implant earlier this year.
Crédit Mutuel Innovation led the financing round, while the European Innovation Council also joined in. Existing investors Wellingotn partners, Bpifrance, Supernova Invest, Hil-Invent, b-to-v Partners and Financière Arbevel also contributed.
“On behalf of our entire exceptional team and the patients whose lives have been restored thanks to our technology, we are grateful to our investor partners for their continued support as we approach the critical milestone of launching our pivotal clinical trial,” said Hamid Lamraoui, UroMems co-founder and CEO. “The confidence of our new and existing investors combined with the strength of our compelling results and tremendous physician interest shows the high potential of our technology. This brings us one step closer to delivering on the massive unmet need for men, women and physicians desperately seeking a better SUI treatment option.”
